At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
TAK-041 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Subjects With Stable Schizophrenia
In Brief
A Phase 2 clinical trial evaluating TAK-041, Placebo, and 1 other intervention for Stable Schizophrenia. Completed, enrolled 23 participants across 1 site.
Detailed Summary
The purpose of the study is to determine whether motivation/reward deficits observed in schizophrenia are attenuated and whether cognitive impairment associated with schizophrenia is improved by add-on TAK-041 administration to antipsychotics in participants with stable schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStable Schizophrenia
CountriesUnited Kingdom
CollaboratorsTakeda
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartDec 2017
Primary CompletionSep 2019
Study CompletionNov 2019
TodayJul 2026
First PostedOct 24, 2017
Enrollment StartDec 21, 2017
Primary CompletionSep 11, 2019
Study CompletionNov 6, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.7 years ago
Interventions
TAK-041drug
TAK-041 suspension
Placebodrug
TAK-041 placebo-matching suspension
Second Generation Antipsychotics (SGA)drug
Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.